An economic analysis in Palestine found that including rotavirus in the routine immunization program is a cost-effective intervention in children under 5 years old. The study estimated that between 2016–2025, rotavirus vaccination in Palestine has the potential to avert approximately 101,000 severe episodes of rotavirus gastroenteritis cases. Avoiding these treatment costs could lead to estimated savings of approximately $14 million for the health system and approximately $22 million for the society (in 2018 US dollars).
Full Citation:
Debellut F, Jaber S, Bouzya Y et al.. 2020. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs impact and cost-effectiveness of ROTARIX and ROTAVAC. PLoS ONE. 15(2).
Title of Article: Introduction of rotavirus vaccination in Palestine: An evaluation of the costs impact and cost-effectiveness of ROTARIX and ROTAVAC
Author(s): Debellut F, Jaber S, Bouzya Y et al.
Publication Year: 2020
Publication Name: PLoS ONE
Publication Volume: 15(2)
Publication Source URL: https://doi.org/10.1371/journal.pone.0228506
DOI (Digital Object Identifier): 10.1371/journal.pone.0228506
Topics: Economics & Return on Investment
Disease Vaccines: Diarrhea | Rotavirus
Countries: Occupied Palestinian territory
WHO Regions: Eastern Mediterranean